UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit

A securities class action alleges Unicycive Therapeutics told shareholders for six months that its OLC application was on track without verifying through its own inspection whether the manufacturer tied to the FDA's prior rejection had corrected any issues. The statement reports an allegation, not a court finding or a new FDA decision.